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Introduction
Although prostate cancer is the most common cancer in American men, there is significant controversy about the role of treatment for patients with organ-confined disease. Practice guidelines recommend that these patients can be offered radiation therapy, surgery, or observation based on their tumor characteristics, prostate-specific antigen (PSA) level, age, comorbidities, and preferences.
Another potential treatment modality is androgen deprivation therapy (ADT) as monotherapy for localized prostate cancer. Although ADT has a well-defined role in patients with metastatic disease [1] or with high-risk localized disease undergoing radiotherapy [2] , its role as monotherapy (also called primary ADT [PADT] ) in patients with localized disease has not been established in clinical trials. Therefore, PADT is not recommended by the National Comprehensive Cancer Network or the Hormone Therapy Study Group for nonmetastatic disease [3, 4] . Practice-pattern surveys, however, suggest that its use is not uncommon: Data from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) database found that 14% of men with clinically localized disease received PADT [5] .
Emergingdatasuggestthepotentialforlong-termtoxicities associated with ADT such as increased risk of osteoporosis [6] , cardiovascular disease, and diabetes [7] . Since patients with organ-confined well-differentiated and moderately differentiated prostate cancer might otherwise be candidates for expectant management, it is important to understand the impact of PADT on survival among men who do not undergo initial treatment with radiation therapy or surgery.
To better characterize the role of PADT on overall survival, we examined a population-based sample of men with well-differentiated and moderately differentiated organ-confined prostate cancer who did not receive radiation therapy or surgery in the first 6 mo after diagnosis.
Methods

Data source
We used the linked Surveillance, Epidemiology, and End Results (SEER)
Medicare database. SEER is a population-based cancer registry encompassing approximately 14% of the US population. SEER includes information on tumor histology, size, and grade [8] . 
Tumor stage
We used clinical extension information provided by SEER to determine tumor stage. Tumors were categorized as T2a and below versus T2b-T2c. 
Treatment
Survival
Survival was defined as the interval from the date of diagnosis to the Medicare inpatient claims, outpatient claims, and Part B claims during the 90 d prior to diagnosis. Comorbidities were identified using a modification of the methods described by Elixhauser et al [9] . In our analysis, cancer diagnosis was not considered a comorbidity; however, stroke and cardiovascular disease were included based on the relatively high prevalence of these conditions in our population. We calculated the odds of receiving ADT based on the number of comorbidities (zero, one, two, three, or more).
2.3.5.2. Demographics. Age, marital status, race, year of diagnosis, and SEER registry were provided by SEER. Patients were classified as living in a rural area if they lived in a county with <20 000 residents; the remaining patients were classified as living in an urban area. We used
median household income per census tract and percent of the census tract with a 4-yr college education as proxies for socioeconomic status.
Statistical analysis
Summary statistics were constructed using frequencies and proportions for categoric variables and means and medians for continuous variables.
We used propensity scores to balance observed covariates between the PADT arm and the observation arm. Propensity scores are the probability that a patient will receive therapy based on known covariates [10, 11] .
We calculated propensity scores using multiple logistic regression with receipt of PADT as the outcome of interest. Demographics, tumor characteristics, and comorbidities were independent variables. Propensity scores were then used to group patients into quintiles according to the probability of receiving active treatment based on each patient's baseline known characteristics. This has been shown to remove >90% of the bias resulting from each of the covariates [12] . We used Student t tests and x 2 tests to determine whether these covariates were balanced within quintiles; all variables, with the exception of tumor size, were balanced between the PADT and the observation arms.
We measured the impact of receiving PADT on overall survival (OS) using a Cox proportional hazards regression and prostate-cancerspecific mortality (PCSM) and non-prostate-cancer-specific mortality (NPCSM) using a competing risk proportional hazards regression, controlling for propensity score as a continuous variable and adjusting for imbalanced covariates [13] . In both, we controlled for propensity score using a restricted cubic spline [14] . We included tumor size in the models since we were not able to achieve complete balance in this 
variable. We further estimated the effects on OS PCSM within propensity score quintiles with PADT and tumor size as the covariates. We tested proportionality of hazards for the treatment effect by including treatment interacted with time as a time-dependent covariate in the primary models of interest.
We performed a sensitivity analysis to measure the potential effect an unmeasured confounder might have on our results [15, 16] . 
Results
Our final cohort for analysis comprised 16 924 patients, of whom 4316 (25.5%) received PADT during the first 6 mo after diagnosis. Baseline characteristics are shown in Table 1 . Table 2 shows the results of the multivariable analysis. At the end of the study period, 6369 patients (37.63%) had died. Some 563 patients had died of prostate cancer. Median survival by treatment shown in Table 3 . After propensity score adjustment, there was a statistically significant increased risk of death in the PADT group (hazard ratio [HR]: 1.19; 95% confidence interval [CI]: 1.13-1.27). This persisted in all five quintile groups (Table 3 ). We also found that patients who received PADT had a higher risk of PCSM (subdistribution hazard ratio [sHR]: 2.22; 95% CI: 1.87-2.65) compared to those who were observed ( Table 4) . The NPCSM appeared similar in both groups (sHR: 1.06; 95% CI: 1.00-1.13; p = 0.057). The Kaplan-Meier survival curves for OS and the cumulative incidence curves for PCSM and non-PCSM are shown in Figs. 1-3 .
The effect of PADT on survival varied over time (for interaction between time in years and PADT as a time varying covariate, p = 0.017). PADT did not have a statistically significant baseline impact on survival (HR: 1.05; 95% CI: 0.93-1.18), but the hazard ratio increased by a multiple of 1.03 (95% CI: 1.01-1.05) for each additional year in follow-up. This suggests that the effects of PADT on survival may not be immediate but may take some time to appear.
Sensitivity analysis
In nonrandomized studies, an observed treatment effect may reflect the effects of unmeasured confounders. The objective of the sensitivity analysis is to assess the effects of an unmeasured confounder (UC) on the estimated treatment effect hazard ratio. Table 4 demonstrates the effects of an UC on the estimated hazard ratio for treatment versus observation. An example of an unmeasured confounder could be ''poor functional status.'' These sensitivity analyses are based on the estimated propensity score and tumor size adjusted hazard ratio for treatment (HR: 1.19; 95% CI: 1.13-1.27). The treatment effect (the hazard ratio) is affected by the prevalence of the UC in the treated and untreated groups and the hazard associated with the UC, which is assumed to be the same in the treated and untreated groups.
In our sensitivity analysis, we assumed that the unmeasured confounder would have a prevalence of 10-30% in the treated group and varied the increased risk of death associated with the unmeasured confounder between 1.25 and 3.25. We varied the prevalence of the UC in the observation group to determine how imbalanced the distribution of the UC would need to be to influence the statistical significance of the results.
We demonstrated that a modest imbalance in the prevalence of an UC that is associated with a high risk of death (HR: 3.25), or marked imbalance in an UC that is associated with a modest risk of death (HR: 1.25) would make the lower bound of the 95% confidence interval crosses one and not be statistically significant (Table 4 , bolded). Only in extreme circumstances, such as marked imbalance in the prevalence of an UC that is associated with a very high HR of death, would the results completely reverse and favor treatment with PADT. These scenarios in which the upper bound of the CI falls <1 (signifying a survival benefit associated with PADT) are shaded.
Discussion
In this observational study of patients with localized prostate cancer who did not receive active therapy with radiation therapy or surgery within 6 mo after diagnosis, we found that 25% were treated with PADT, despite no available clinical trial data or practice guidelines to support this practice. There was no improvement in overall survival, and our results suggest that it is possible that these patients may have actually had worse long-term outcomes. HR = hazard ratio; PADT = primary androgen deprivation therapy. * Adjusted for propensity score and tumor size in the whole cohort and for tumor size in the quintiles. Fig. 2 -Prostate cancer-specific mortality. 0 0 9 ) 6 0 9 -6 1 6 We believe that this finding is of potential clinical significance because it supports practice guidelines that do not recommend PADT for patients with organ-confined well-differentiated or moderately-differentiated prostate cancer [3] . Although studies have suggested a potential benefit of radiation therapy or surgery for these patients [17, 18] , both can be associated with side effects. Cohort studies suggest that these individuals may have a relatively low risk of disease progression, even if conservatively managed [19, 20] . Therefore, expectant management is considered an acceptable strategy for many patients with organ confined well-or moderately differentiated disease, particularly among those with other significant comorbidities or those who are hesitant to proceed with radiation therapy or surgery due to potential side effects.
For many patients, ''doing nothing'' for their prostate cancer can cause significant anxiety. More so than tumor characteristics, high anxiety levels have been associated with a greater probability of receiving active treatment in a cohort of patients who originally chose expectant management [21] . Because PSA levels will initially decline with ADT in most patients with hormone-naïve prostate cancer, patients and physicians may perceive ADT as effective treatment that is less invasive than radiation therapy or surgery. Our findings found no benefit to PADT and possibly greater mortality, presenting a strong argument against its use as primary therapy in these patients.
There are several plausible biologic explanations for this finding. Preclinical data suggest that reduced circulating androgen levels may promote the growth of more aggressive prostate cancer tumors [22, 23] . In mouse models of early stages of carcinogenesis, androgen independence can develop despite the lack of overt cancer progression [24] . Therefore, it is possible that patients who received PADT may be at higher risk of developing androgenindependent disease earlier than those who did not receive PADT. Since patients with metastatic androgen-independent prostate cancer have a limited life expectancy, this could explain the worse cancer-specific outcomes in patients treated with PADT.
There is evidence that hypogonadism associated with long-term ADT has placed patients at increased risk of longterm health complications that can contribute to noncancer mortality. Analyses of SEER Medicare data found a higher rate of diabetes, coronary artery disease, and cardiac events in patients who received LHRH agonists [7] . Other studies of patients undergoing prostatectomy or radiation therapy have also shown worse cardiac outcomes in patients treated with ADT [25] [26] [27] . Additionally, ADT has also been associated with an increased risk of osteoporosis and fracture [6] .
This research has several strengths. Randomized studies of localized prostate cancer have proved difficult to complete. The research provides insight into a common practice (ie, PADT) for which there are no existing randomized data. By using SEER Medicare data, we were able to examine the outcomes of treatment in patients aged 65 yr, a group that is traditionally underrepresented in clinical trials. Our study also has a long follow-up, which allowed us to measure overall survival as our primary end point rather than necessitating reliance on intermediate markers such as biochemical progression that might not correlate with survival and might fail to reflect the increased risk of comorbidities associated with ADT.
Our findings are consistent with those reported by LuYao et al [28] , who used an instrumental variable analysis of SEER Medicare data to measure the benefit of PADT on overall survival in a group of patient with organ-confined disease. They did not find a survival advantage associated with ADT use, with the exception of a non-statistically significant benefit in the group with poorly differentiated disease. Since patients with untreated high-grade disease have a short disease-specific survival, it is not surprising that the use of PADT in these patients may have improved survival compared with no treatment. In our study, we specifically excluded patients with high-grade disease because they are considered to be at high risk for progressive disease and generally are not considered candidates for observation protocols. Therefore, our results complement Lu-Yao's findings, since they show that despite different methods of statistical adjustment (propensity scores vs instrumental variables), we both found no survival advantage associated with PADT.
Our results are also similar to those reported by McLeod et al [29] , who found that patients with localized disease who received high doses of the antiandrogen bicalutamide (150 mg/d) had no clinical benefit compared with patients who were observed. Similar to our findings, there was a non-statistically significant benefit in progression-free survival favoring the observation arm (HR: 1.16; 95% CI: 0.99-1.37). Although the efficacy of high-dose bicalutamide had not been directly compared to ADT, our findings support this clinical trial data suggesting that hormonal therapy as monotherapy does not confer a survival advantage compared with no treatment in men with localized prostate cancer. Since our study used an observational cohort rather than a randomized controlled trial design, it is important to interpret these findings within the limitations of observational data. Since patients were not randomized, treatment and observation groups may differ in both measured and unmeasured ways that are associated with differences in survival. The traditional concern is that men who are offered treatment may be healthier than men who are not, raising questions about the validity of any apparent benefit of treatment. One would expect, however, that healthier, more motivated patients might seek out treatment with PADT, and it is difficult to imagine a clinical scenario where less healthy patients would be preferentially offered PADT preferentially over observation. Therefore, it is unlikely that our findings were due entirely to selection bias.
Additionally, SEER Medicare data do not provide information on PSA levels or the indication for ADT. It is possible that the PADT group may have included patients with higher risk disease by PSA criteria, accounting for the worse outcomes. Our sensitivity analyses (Table 4) show the possibility that a modest imbalance in high PSA or another unmeasured confounder could have reversed the slightly worse outcomes in the PADT arm, resulting in no survival difference between the arms (Table 4 , bolded). A much more extreme scenario, however, would need to be present to reverse the findings and to result in a statistically significant survival advantage favoring PADT (Table 4 , shaded). This supports the hypothesis that PADT most likely provides no survival benefit and, in fact, may shorten survival relative to no treatment.
It is possible that deaths of patients undergoing treatment with PADT may be more likely to be attributed to prostate cancer than are deaths of patients who undergo observation. This factor may explain the higher PCSM in patients who received PADT.
Conclusions
Although observational studies such as ours should be considered hypothesis generating, our findings may have important clinical implications, given the significant controversial role of treatment for men with localized prostate cancer. Physicians who are counseling patients should convey that observation is an acceptable option for many patients; ''doing something'' via PADT may fail to confer a survival advantage and, instead, may put the patient at risk for toxicity.
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